Suppr超能文献

原发性骨质疏松症药物治疗起始的骨折风险评估工具判断准确性。

Accuracy of the Fracture Risk Assessment Tool for judging pharmacotherapy initiation for primary osteoporosis.

机构信息

Department of Orthopaedic Surgery, Yokohama Ekisaikai Hospital, 1-2 Yamada-cho, Naka-ku, Yokohama City, 231-0036, Japan.

Department of Orthopaedic Surgery, Yokohama City University, 3-9, Fukuura, Kanazawa-ku, Yokohama City, 236-0004, Japan.

出版信息

J Bone Miner Metab. 2022 Sep;40(5):860-868. doi: 10.1007/s00774-022-01356-0. Epub 2022 Aug 10.

Abstract

INTRODUCTION

This study aimed to determine whether the Fracture Risk Assessment Tool (FRAX) is useful in assessing the criteria for the initiation of pharmacotherapy for primary osteoporosis based on the current diagnostic criteria in Japan.

MATERIALS AND METHODS

We enrolled 614 patients aged ≥ 40 years (average, 77.0 years) who were eligible for primary osteoporosis evaluation. Bone mineral density measurements of the lumbar spine, total hip, and femoral neck using ALPHYS LF (FUJIFILM, Tokyo, Japan) and imaging studies involving the lumbar spine were obtained and the FRAX scores of each patient were calculated with and without the T-score of the femoral neck. The receiver operating characteristic curve analysis method was used to calculate the cut-off FRAX scores with reference to the criteria for initiating pharmacotherapy for osteoporosis; the accuracies of both FRAX scores were compared.

RESULTS

The FRAX score calculated with the T-score was more accurate for hip fracture risk assessment [cut-off value 5.5%; the area under the curve (AUC) 0.946] than for major osteoporotic fracture risk assessment (cut-off value 17.0%; AUC 0.924) in judging the criteria (p = 0.001). Conversely, the FRAX score calculated without the T-score was equally accurate for hip fracture risk assessment (AUC 0.796) and major osteoporotic fracture risk assessment (AUC 0.806) (p = 0.23).

CONCLUSION

The FRAX score can accurately assess the criteria for initiating pharmacotherapy for primary osteoporosis based on the current Japanese diagnostic criteria, especially when the T-score is used.

摘要

简介

本研究旨在确定 Fracture Risk Assessment Tool(FRAX)是否可用于评估基于日本现行诊断标准的原发性骨质疏松症起始药物治疗标准。

材料和方法

我们纳入了 614 名年龄≥40 岁(平均 77.0 岁)符合原发性骨质疏松症评估条件的患者。使用 ALPHYS LF(FUJIFILM,东京,日本)测量腰椎、全髋和股骨颈的骨密度,并进行腰椎影像学检查,计算每位患者的 FRAX 评分,同时考虑和不考虑股骨颈 T 值。采用受试者工作特征曲线分析方法,参照骨质疏松症起始药物治疗标准计算截断 FRAX 评分,比较两种 FRAX 评分的准确性。

结果

考虑股骨颈 T 值的 FRAX 评分在评估髋部骨折风险时(截断值 5.5%;曲线下面积 AUC 0.946)比评估主要骨质疏松性骨折风险时(截断值 17.0%;AUC 0.924)更准确(p=0.001)。相反,不考虑股骨颈 T 值的 FRAX 评分在评估髋部骨折风险(AUC 0.796)和主要骨质疏松性骨折风险(AUC 0.806)时同样准确(p=0.23)。

结论

FRAX 评分可准确评估基于日本现行诊断标准的原发性骨质疏松症起始药物治疗标准,尤其是考虑股骨颈 T 值时。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验